Custom Skincare Formulation: FDA’s Allergen Rule Is Due This Month
The FDA rule that will require fragrance allergens to be named on US cosmetic labels is targeted for this month and has not published. The federal regulatory agenda lists it as RIN 0910-AI90, “Disclosure of Fragrance Allergens in Cosmetic Labeling”, with a notice of proposed rulemaking dated 11/00/2026 — agency shorthand for “some time in November.” Nine days are left in that window. For anyone commissioning a custom skincare formulation right now, the practical point is that this is a bench decision, not a printing decision: what a label will have to disclose is fixed by the fragrance you sign off months before artwork exists.
What the pending rule covers, and what it does not
The Modernization of Cosmetics Regulation Act of 2022 added section 609(b) to the Federal Food, Drug, and Cosmetic Act, directing FDA to identify substances as fragrance allergens and require that they be disclosed on cosmetic labels. The statutory deadline for the proposal was 29 June 2024. It passed. FDA’s own MoCRA page still lists fragrance allergen labeling among the regulations the law requires it to establish, and a search of the Federal Register returns no FDA fragrance allergen proposed rule to date.
So there is no US fragrance allergen disclosure duty today, no published list, and no compliance date. There is also no reason to treat that as a reprieve. Congress told FDA to consider international requirements, and the EU has already done this — so brands selling in Europe already know roughly what the list looks like.
The EU version is live, and it caught white label rebrands
Commission Regulation (EU) 2023/1545 added 56 fragrance allergens to the 24 already individually labeled under Annex III of the EU Cosmetics Regulation. Each must be named in the ingredient list once it exceeds 0.001% in a leave-on product or 0.01% in a rinse-off one. The European Commission confirms that since 31 July 2026, products that do not comply may no longer be placed on the EU market; stock placed before that date may be made available until 31 July 2028.
The detail worth reading twice comes from Ireland’s regulator. The HPRA’s guidance on fragrance allergen labeling states that if a product is undergoing rebranding — “for example, a white label formulation with new branding” — repackaging, reformulation or relabelling, it may count as being placed on the market as a new product. Taking an existing formula, putting your name on it and launching it is therefore not inherited compliance. It is a new launch, judged against the current rules.
Why “parfum” stops being a complete answer
A fragrance is normally declared as a single ingredient — parfum or aroma — with named allergens added alongside it where the rules demand. That means the disclosure cannot be worked out from the finished product or reverse-engineered from a competitor’s carton. It requires a composition breakdown from whoever supplies the fragrance oil, expressed as percentages in the finished formula rather than percentages of the fragrance concentrate. Those two numbers get confused constantly, and the difference decides whether a substance clears a 0.001% threshold.
Fragrance houses treat full compositions as trade secrets. They will, however, issue an allergen declaration against a named regulatory list at a specific dose rate. The time to request it is while the formula is still open, because the alternatives later are reformulating or reprinting.
What to settle before the formula locks
- Ask your fragrance supplier for an allergen declaration tied to your actual dose rate in the finished product, not to the concentrate.
- Get it against the current EU Annex III list — the published one — rather than waiting for a US list that does not exist yet.
- Decide early whether you will ever sell into the EU or UK. Fragrance choice is cheap to change now and expensive to change after artwork, inventory and a filed safety assessment exist.
- Keep the declaration in the same file as your safety substantiation records. If the allergen profile changes because the dose rate changed, both documents move together.
- Remember who carries this. Under MoCRA the responsible person is the manufacturer, packer or distributor whose name appears on the label — in a private label project, that is normally the brand, not the factory.
- Treat a rebrand or a packaging change as a new launch for labeling purposes, not as a continuation of someone else’s compliance.
The ordering advantage of asking at the brief stage
There is a structural reason this question belongs at the start. A custom formulation at Moe’s Group carries a 1,000-unit minimum, and an existing, ready-to-go formula carries a 200-unit minimum. Either way, the fragrance brief is written before anyone fills anything. A brand that specifies “supply an allergen declaration at my dose rate” in the brief gets the document as part of the formulation work. A brand that asks after approving the formula is asking a fragrance house to document a decision that has already been made, on someone else’s timeline.
None of this requires guessing what FDA will publish. The EU list and thresholds are public, and the brands that mapped their fragrances against them will read the US proposal as a checklist rather than a reformulation project.
If you are scoping a custom skincare formulation and want the fragrance allergen question handled inside the brief instead of after it, talk to us about your project.
— The Moe’s Group newsroom